Prognostic implications of chronic heart failure and utility of NT-proBNP levels in heart failure patients with SARS-CoV-2 infection
| Autor: | Sonia Ruiz-Bustillo, Eduard Solé-González, Sandra Valdivielso-More, Núria Farré, Miren Vicente Elcano, Isaac Subinara, Laia Carla Belarte-Tornero, Hector Cubero-Gallego, Alicia Calvo-Fernández, Paula Cabero, Beatriz Vaquerizo, Cristina Soler |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lcsh:Medicine Heart failure 030204 cardiovascular system & hematology Article 03 medical and health sciences 0302 clinical medicine Internal medicine medicine In patient 030212 general & internal medicine cardiovascular diseases health care economics and organizations biology Troponin T business.industry SARS-CoV-2 lcsh:R Hazard ratio COVID-19 General Medicine medicine.disease Prognosis Troponin Confidence interval humanities Coronavirus NT-proBNP Cohort cardiovascular system biology.protein business human activities Biomarkers circulatory and respiratory physiology |
| Zdroj: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 10, Iss 323, p 323 (2021) Volume 10 Issue 2 |
| Popis: | Background: The prevalence and prognostic value of chronic heart failure (CHF) in the setting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has seldom been studied. The aim of this study was to analyze the prevalence and prognosis of CHF in this setting. Methods: This single-center study included 829 consecutive patients with SARS-CoV-2 infection from February to April 2020. Patients with a previous history of CHF were matched 1:2 for age and sex. We analyze the prognostic value of pre-existing CHF. Prognostic implications of N terminal pro brain natriuretic peptide (NT-proBNP) levels on admission in the CHF cohort were explored. Results: A total of 129 patients (43 CHF and 86 non-CHF) where finally included. All-cause mortality was higher in CHF patients compared to non-CHF patients (51.2% vs. 29.1%, p = 0.014). CHF was independently associated with 30-day mortality (hazard ratio (HR) 2.3, confidence interval (CI) 95%: 1.26&ndash 2.4). Patients with CHF and high-sensitivity troponin T < 14 ng/L showed excellent prognosis. An NT-proBNP level > 2598 pg/mL on admission was associated with higher 30-day mortality in patients with CHF. Conclusions: All-cause mortality in CHF patients hospitalized due to SARS-CoV-2 infection was 51.2%. CHF was independently associated with all-cause mortality (HR 2.3, CI 95% 1.26&ndash 4.2). NT-proBNP levels could be used for stratification risk purposes to guide medical decisions if larger studies confirm this finding. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|